Tocotrienol and Bevacizumab in Metastatic Colorectal Cancer

Inclusion Criteria: * Histopathologically verified adenocarcinoma of the colon or rectum * Metastatic disease * Planned treatment with FOLFOX or capecitabine combined with bevacizumab * Evaluable disease according to RECIST 1.1 * Performance status 0-2 * Expected survival ≥ 3 months * Patient acceptance to collection of blood samples for translational research * Age ≥ 18 years * Contraception during and 6 months after last dose for women of childbearing potential (less than one year amenorrhea and not undergone hysterectomy, bilateral salpingectomy or bilateral oophorectomy) and for male patients with a fertile partner. Hormonal contraception, intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomized partner, or sexual abstinence is accepted. * Adequate bone marrow function, liver function, and renal function (within 7 days prior to inclusion): * WBC ≥ 3.0 x 109/l or neutrophils (ANC) ≥ 1.5 x 10\^9/l * Platelet count ≥ 100 x 10\^9/l * Hemoglobin ≥ 6.0 mmol/l * Serum bilirubin ≤ 2.0 x ULN * Serum transaminase ≤ 2.5 x ULN * Serum creatinine ≤ 1.5 ULN * Urine dipstick for protein ≤ 2+, if the dipstick shows protein ≥ 2+, 24 hour urine testing must be performed and show protein contents ≤ 1g. * Written and orally informed consent Exclusion Criteria: * Other active malignant disease within 5 years prior to inclusion in the study. * Other experimental therapy within 28 days prior to treatment initiation. * Underlying medical disease not adequately treated. * Surgery, including open biopsy, within 4 weeks prior to first dose of bevacizumab. * Cerebral vascular attack, transient ischemic attack or subarachnoid hemorrhage within six months before start of treatment * Bleeding tumor * Pregnant or breastfeeding women * Fertile patients not willing to use effective methods of contraception during treatment and for six months after end of treatment. * Hypersensitivity to one or more active substances or auxiliary substances